Momenta's Humira biosimilar succeeds in key psoriasis study

(Reuters) – U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc’s top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *